GV, a corporate venturing arm of US-based internet technology group Alphabet, has hired Daniel Lynch as an executive venture partner and appointed Mojca Skoberne to an entrepreneur-in-residence position.
Lynch is curently serving as chairman of five biopharmaceutical companies: Xilio Therapeutics, SpringWorks Therapeutics, Blueprint Medicines, Translate Bio and BlueBirdBio, having previously held similar positions at peers including Surface Oncology, Bind Therapeutics and Nimbus Discovery.
David Schenkein, a general partner for GV who oversees its life sciences investment team, said of Lynch in a blog post: “We are thrilled to have him to bring his meaningful coaching work to a newly created role across the GV portfolio.
“He will partner with CEOs and executives as a trusted coach and adviser to emerging life sciences companies as they tackle various startup challenges and build great businesses…Dan will also identify new investments, help make critical investment decisions and mentor our growing life sciences team.”
Skoberne on the other hand had been a senior vice-president for gene therapy developer Repertoire Immune Medicines, where she offered her expertise in immunology, cancer and infectious diseases. Her role at GV will involve her mentoring entrepreneurs building immunotherapy-themed companies.
The moves came in the wake of Blake Byers leaving his life sciences-focused general partner role at GV earlier this month.
Photos of Dan Lynch and Mojca Skoberne courtesy of GV.
